Expression of calcium-binding protein A9 in cervical cancer and its relationship with therapeutic effect
10.3760/cma.j.cn115355-20221122-00735
- VernacularTitle:钙结合蛋白A9在子宫颈癌中的表达及其与疗效的关系
- Author:
Ni CHEN
1
;
Xiping FANG
Author Information
1. 恩施土家族苗族自治州中心医院肿瘤科，恩施 445000
- Keywords:
Uterine cervical neoplasms;
Calcium-binding proteins;
Drug therapy;
Treatment outcome
- From:
Cancer Research and Clinic
2023;35(11):827-832
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression of calcium binding-protein A9 (S100A9) in cervical cancer and its relationship with the efficacy of TC (paclitaxel+carboplatin) regimen chemotherapy in patients.Methods:A total of 119 patients with cervical cancer who were scheduled to undergo TC regimen chemotherapy in the Central Hospital of Enshi Tujia and Miao Autonomous Prefecture from July 2017 to May 2021 were selected to conduct a prospective study. The tissue samples of all patients were obtained by biopsy before treatment, and the expressions of S100A9, matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) in cervical cancer tissues and paracancerous normal tissues were detected by immunohistochemistry. The correlation of S100A9 expression with MMP-9 and VEGF expressions in cervical cancer tissues were analyzed by using Spearman method. The patients were divided into the effective group (complete remission+partial remission) and the ineffective group (stable disease+progressive disease) according to the effectiveness of chemotherapy, and the expressions of S100A9, MMP-9 and VEGF in cervical cancer tissues of the two groups were compared. The influencing factors for TC regimen chemotherapy efficacy were analyzed by using multivariate logistic regression method.Results:Compared with paracancerous tissues, the positive expression rates of S100A9 [90.76% (108/119) vs. 45.38% (54/119)], MMP-9 [55.46% (66/119) vs. 17.65% (21/119)] and VEGF [78.99% (94/119) vs. 24.37% (29/119)] were all elevated in cervical cancer tissues ( χ2 values were 47.03, 36.69 and 71.09, all P < 0.001). The S100A9 expression in cervical cancer tissues was positively correlated with MMP-9 and VEGF expressions ( r values were 0.619 and 0.784, both P < 0.001). The effective rate of TC regimen chemotherapy was 47.06% (56/119). The positive expression rate of S100A9 in cervical cancer tissues of the effective group was higher than that of the ineffective group [98.21% (55/56) vs. 84.13% (53/63), P < 0.05], while the positive expression rates of MMP-9 [35.71% (20/56) vs. 73.02% (46/63)] and VEGF [67.86% (38/56) vs. 88.89% (56/63)] were lower than those of the ineffective group (both P < 0.001). Multivariate logistic regression analysis showed that clinical stage Ⅳ ( OR = 2.707, 95% CI 1.865-4.119, P < 0.05), lymph node metastasis ( OR = 4.468, 95% CI 3.221-5.823, P < 0.001), deep myometrial invasion ( OR = 5.686, 95% CI 4.308-7.247, P < 0.001), vascular tumor thrombus or parauterine invasion ( OR = 3.758, 95% CI 2.584-5.163, P < 0.001), MMP-9 positive expression in cancer tissues ( OR = 3.904, 95% CI 2.876-5.228, P < 0.001) and VEGF positive expression in cancer tissues ( OR = 2.609, 95% CI 1.793-4.052, P < 0.05) were the risk factors affecting the TC regimen chemotherapy efficacy, while the S100A9 positive expression in cancer tissues was the protective factor for TC regimen chemotherapy efficacy ( OR = 0.660, 95% CI 0.417-0.854, P < 0.05). Conclusions:The expression of S100A9 in cervical cancer tissues increases and correlates with MMP-9 and VEGF expressions. The high expression of S100A9 could increase the effectiveness of TC regimen chemotherapy in cervical cancer patients, while clinical stage Ⅳ, lymph node metastasis, deep muscle invasion, vascular tumor thrombus or parauterine invasion, MMP-9 positive expression and VEGF positive expression may increase the risk of ineffective chemotherapy with TC regimen in patients.
